QBiotics Group Limited

Investment Highlights

Company Overview

• 

  Simultaneous human and veterinary development model

  Delivers earlier returns and reduces risks for human development

• 

  Treating tumours & wounds with high-value, inter-related programmes

  Human oncology & would healing pharmaceutical

• 

  Proprietary drug discovery platform EcoLogic™

  Offer potential for long term growth targeting only the best biologically active molecules

• 

  Veterninary pharmaceuticals already in the market

  Marketing veterinary drug STELFONTA in the US, Europe and Australia

QBiotics research and development program is based on compounds derived from the Australian tropical rainforest.

The product focus addresses unmet medical needs for humans and companion animals, with a concentration on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.

QBiotics is an Australian life sciences company, inspired by nature to improve human and animal health.

Pursuing both monotherapy and combination therapy avenues in clinical trials to test efficacy and safety – results of these studies provided a clinically relevant and highly validated model for cancer in humans

Current Market Cap >A$500M

850,000 shares available

 

Additional Information

• Financials

• June 2022

  Annual Report

Team

• Management
• Directors

• Dr Peter Schmidt

  Chief Operating Officer

  

• Michael Wenzel

  Chief Financial Officer

• Mary Phipps

  Chief Marketing Officer

• Dr Richard Yocum

  Chief Medical Officer

  

• Roberta Bozzili

  Chief Legal & Commercial Officer

• Ebru Davidson

  General Counsel

  

• Dr Tracey Mynott

  Business Development Manager

• Dr Sam Yurdakul

  Director of Prduct Development

  

• Rick Holliday-Smith AM

  Non-Executive Chairman

• Dr Victoria Gordon

  Managing Director & CEO

• Dr Paul Reddell

  Executive Director & Chief Scientific Officer

• Nicholas Moore

  Non-Executive Director

• Dr Susan Foden

  Non-Executive Director

• Andrew Denver

  Non-Executive Director

• Professor Bruce Robinson AC

  Non-Executive Director

• Associate Professor Steven Ogbourne

  Non-Executive Director

• Neville Mitchell

  Non-Executive Director

• Hamish Corlett

  Non-Executive Director

News

• March 2022

  Development to speed drugs to market

  Read more

• June 2021

  Qbiotics concludes successful A$85M capital raise

  Read more